Australia outlines roles and duties of IVD sponsors and manufacturers
This article was originally published in Clinica
Australia's Therapeutic Goods Administration has issued more details on the conformity assessment process under its new in vitro diagnostics regulations that came into force in July last year. Specifically, the TGA has published documents distinguishing between the responsibilities and obligations of IVD sponsors and manufacturers under the new framework.
You may also be interested in...
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.